Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why? [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 70-year-old man with urothelial cancer of the bladder (UBC) metastatic to the pelvic and retroperitonea...
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Galsky, Domingo-Domenech, Sfakianos, Ferket Tags: Oncology Grand Rounds Source Type: research

When Can a Salvage Therapy (T-DM1) Take the Lead? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Mahtani, Vogel Tags: Chemotherapy EDITORIALS Source Type: research

Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Penson, Resnick Tags: Diagnosis & Staging EDITORIALS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Targeted Therapies in Older Adults With Breast Cancer: What Do We Know? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Strulov Shachar, Hurria, Muss Tags: CORRESPONDENCE Source Type: research

Reply to K. Lin et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Smith Tags: CORRESPONDENCE Source Type: research

Dangers of Excluding Margin Status From a Ductal Carcinoma In Situ Prognostic Score [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Lin, Lagios, Silverstein Tags: CORRESPONDENCE Source Type: research

Reply to P. de Boissieu et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Low, Bovbjerg, Bartlett Tags: CORRESPONDENCE Source Type: research

Impact of Depression in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: de Boissieu, Crespel, Duminil, de Mestier Tags: CORRESPONDENCE Source Type: research

Reply to M. Nishino [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Hodi, Wolchok Tags: CORRESPONDENCE Source Type: research

Pseudoprogression and Measurement Variability [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Nishino Tags: CORRESPONDENCE Source Type: research

Talking to Children With Cancer: Sometimes Less Is More [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Korones Tags: End of life issues, Patient communication, All Art of Oncology Articles Source Type: research

Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? [STATISTICS IN BRIEF]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: AHern Tags: Clinical Trials, Statistics in Oncology STATISTICS IN BRIEF Source Type: research

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytored...
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Wright, Bohlke, Armstrong, Bookman, Cliby, Coleman, Dizon, Kash, Meyer, Moore, Olawaiye, Oldham, Salani, Sparacio, Tew, Vergote, Edelson Tags: ASCO Guidelines, Epidemiology, Diagnosis & Staging, Surgery, Chemotherapy ASCO SPECIAL ARTICLE Source Type: research

MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents [BIOLOGY OF NEOPLASIA]
Conclusion A novel MEF2D-BCL9 fusion we identified characterizes a novel subset of pediatric ALL, predicts poor prognosis, and may be a candidate for novel molecular targeting. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Suzuki, Okuno, Kawashima, Muramatsu, Okuno, Wang, Kataoka, Sekiya, Hamada, Murakami, Kojima, Narita, Narita, Sakaguchi, Sakaguchi, Yoshida, Nishio, Hama, Takahashi, Kudo, Kato, Kojima Tags: Translational Oncology, Acute Lymphoblastic Leukemia BIOLOGY OF NEOPLASIA Source Type: research

Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium [REVIEW ARTICLE]
Purpose Female survivors of childhood, adolescent, and young adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential exposure of the ovaries, have an increased risk of premature ovarian insufficiency (POI). Clinical practice guidelines can facilitate these survivors’ access to optimal treatment of late effects that may improve health and quality of survival; however, surveillance recommendations vary among the existing long-term follow-up guidelines, which impedes the implementation of screening. Patients and Methods The present guideline was developed by using an evidence-based ...
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: van Dorp, Mulder, Kremer, Hudson, van den Heuvel-Eibrink, van den Berg, Levine, van Dulmen-den Broeder, di Iorgi, Albanese, Armenian, Bhatia, Constine, Corrias, Deans, Dirksen, Gracia, Hjorth, Kroon, Lambalk, Landier, Levitt, Leiper, Meacham, Mussa, Negge Tags: Non-ASCO Guidelines, Long Term Survival & Late Effects REVIEW ARTICLE Source Type: research

How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer [Surgical Oncology]
Conclusion To our knowledge, our study provides the first empirically based estimates of occult nodal disease risk in patients after surgery for papillary thyroid cancer as a function of primary tumor stage and number of LNs examined. Our estimates provide an objective guideline for evaluating adequacy of LN yield for surgeons and pathologists in the treatment of papillary thyroid cancer, and especially intermediate-risk disease, for which use of adjuvant radioactive iodine and surveillance intensity are not currently standardized. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Robinson, Thomas, Dinan, Roman, Sosa, Hyslop Tags: Bioinformatics, Prognostic Studies, Diagnosis & Staging, Surgery, Diagnosis & Staging, Surgery Surgical Oncology Source Type: research

Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality [Hematologic Malignancy]
Purpose Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is one important treatment option for patients with aggressive adult T-cell leukemia/lymphoma (ATLL). Mogamulizumab (anti-CCR4 monoclonal antibody; Mog) was recently approved as a treatment for ATLL in Japan. Major concerns exist about the possible adverse effects of pretransplantation Mog because Mog depletes regulatory T cells for several months. We assessed the impact of pretransplantation Mog on clinical outcomes after allo-HSCT. Patients and Methods We included 996 allo-HSCT recipients age 70 years or younger with aggressive ATLL who were given th...
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Fuji, Inoue, Utsunomiya, Moriuchi, Uchimaru, Choi, Otsuka, Henzan, Kato, Tomoyose, Yamamoto, Kurosawa, Matsuoka, Yamaguchi, Fukuda Tags: Lymphoma Hematologic Malignancy Source Type: research

Behavioral, Social, and Emotional Symptom Comorbidities and Profiles in Adolescent Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study [Pediatric Oncology]
Conclusion Behavioral, emotional, and social symptoms frequently co-occur in adolescent survivors of childhood cancer and are associated with treatment exposures and physical late effects. Assessment and consideration of symptom profiles are essential for directing appropriate mental health treatment for adolescent survivors. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Brinkman, Li, Vannatta, Marchak, Lai, Prasad, Kimberg, Vuotto, Di, Srivastava, Robison, Armstrong, Krull Tags: Long Term Survival & Late Effects Pediatric Oncology Source Type: research

Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History [Breast Cancer]
Purpose To evaluate the impact of breast cancer family history and maternal BRCA1/2 mutation on the psychosocial adjustment and perceived risk in girls age 11 to 19 years old. Materials and Methods Girls age 11 to 19 years old with one or more relatives with breast cancer or a familial BRCA1/2 mutation (breast cancer family history [BCFH] positive, n = 208; n = 69 with BRCA1/2-positive mother), peers (BCFH negative, n = 112), and their mothers completed assessments of psychosocial adjustment, breast cancer–specific distress, and perceived risk of breast cancer. Results General psychosocial adjustment did not differ...
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Bradbury, Patrick-Miller, Schwartz, Egleston, Henry-Moss, Domchek, Daly, Tuchman, Moore, Rauch, Shorter, Karpink, Sands Tags: Behavioral and Lifestyle Risk Factors Breast Cancer Source Type: research

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 [Breast Cancer]
Purpose To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity and few adverse effects in advanced breast cancer, in early breast cancer. Patients and Methods International Breast Cancer Study Group (IBCSG) Trial 22-00, a randomized phase III clinical trial, enrolled 1,086 women (1,081 intent-to-treat) from November 2000 to December 2012. Women with estrogen receptor– and progesterone receptor–negative (
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Colleoni, Gray, Gelber, Lang, Thurlimann, Gianni, Abdi, Gomez, Linderholm, Puglisi, Tondini, Kralidis, Eniu, Cagossi, Rauch, Chirgwin, Gelber, Regan, Coates, Price, Viale, Goldhirsch Tags: Chemotherapy Breast Cancer Source Type: research

Efficacy of Mindfulness-Based Cognitive Therapy on Late Post-Treatment Pain in Women Treated for Primary Breast Cancer: A Randomized Controlled Trial [Breast Cancer]
Conclusion MBCT showed a statistically significant, robust, and durable effect on pain intensity, indicating that MBCT may be an efficacious pain rehabilitation strategy for women treated for breast cancer. In addition, the effect on neuropathic pain, a pain type reported by women treated for breast cancer, further suggests the potential of MBCT but should be considered preliminary. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Johannsen, OConnor, OToole, Jensen, Hojris, Zachariae Tags: Quality of Life, Pain Control, Supportive Care Breast Cancer Source Type: research

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer [Thoracic Oncology]
Purpose Anaplastic lymphoma kinase (ALK) rearrangement–positive non–small-cell lung cancers can be effectively treated with an ALK tyrosine kinase inhibitor (TKI) such as crizotinib, but the response magnitude and duration are heterogeneous. Several ALK variants have been identified, but few studies have focused on the effects of different ALK variants on the efficacy of crizotinib. Patients and Methods Among 55 patients treated with crizotinib as the initial ALK-TKI between January 2007 and December 2014, we identified 35 patients with tumor specimens that could be evaluated for ALK variants by reverse transc...
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Yoshida, Oya, Tanaka, Shimizu, Horio, Kuroda, Sakao, Hida, Yatabe Tags: Chemotherapy Thoracic Oncology Source Type: research

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer [Rapid Communication]
Conclusion In this retrospective analysis, patients positive for T790M in plasma have outcomes with osimertinib that are equivalent to patients positive by a tissue-based assay. This study suggests that, upon availability of validated plasma T790M assays, some patients could avoid a tumor biopsy for T790M genotyping. As a result of the 30% false-negative rate of plasma genotyping, those with T790M-negative plasma results still need a tumor biopsy to determine presence or absence of T790M. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Oxnard, Thress, Alden, Lawrance, Paweletz, Cantarini, Yang, Barrett, Janne Tags: Rapid Communications, Translational Oncology Source Type: research

Categorization of Cancer Survivors: Why We Need It [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Surbone, Tralongo Tags: Quality of Care COMMENTS AND CONTROVERSIES Source Type: research

Chemotherapy for Triple-Negative Breast Cancer: Is More Better? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Mayer, Burstein Tags: EDITORIALS Source Type: research

Mindfulness Interventions for Cancer Survivors: Moving Beyond Wait-List Control Groups [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Bower Tags: Pain Control, Complementary & Alternative Medicine EDITORIALS Source Type: research

Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Lin, Shaw Tags: Translational Oncology EDITORIALS Source Type: research

Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Rosell, Karachaliou Tags: EDITORIALS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Retraction [RETRACTION]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Tags: RETRACTION Source Type: research

Can Observational Data Replace Randomized Trials? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: McGale, Cutter, Darby, Henson, Jagsi, Taylor Tags: CORRESPONDENCE Source Type: research

Management and Care of Women With Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Chuang, Feldman, Nakisige, Temin, Berek Tags: CORRESPONDENCE Source Type: research

Reply to J. Jupp et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Hesketh, Bohlke, Kris Tags: CORRESPONDENCE Source Type: research

Pharmacists: Integral to the Management of Chemotherapy-Induced Nausea and Vomiting [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Jupp, Pasetka, Soefje, Schwartz Tags: CORRESPONDENCE Source Type: research

Reply to K. Kroenke et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Basch Tags: CORRESPONDENCE Source Type: research

Symptom Improvement Requires More Than Screening and Feedback [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Kroenke, Cheville Tags: CORRESPONDENCE Source Type: research

A Space to Heal [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: George, Kandasamy Tags: End of life issues, Emotions of the oncologist, Hospice and symptom control, Patient communication, All Art of Oncology Articles Source Type: research

National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer [SPECIAL ARTICLE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Pal, Agarwal, Boorjian, Hahn, Siefker-Radtke, Clark, Plimack Tags: Diagnosis & Staging, Chemotherapy, Translational Oncology SPECIAL ARTICLE Source Type: research

Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose To provide evidence-based guidance on the optimum management of chronic pain in adult cancer survivors. Methods An ASCO-convened expert panel conducted a systematic literature search of studies investigating chronic pain management in cancer survivors. Outcomes of interest included symptom relief, pain intensity, quality of life, functional outcomes, adverse events, misuse or diversion, and risk assessment or mitigation. Results A total of 63 studies met eligibility criteria and compose the evidentiary basis for the recommendations. Studies tended to be heterogeneous in terms of quality, size, and populations. Pr...
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Paice, Portenoy, Lacchetti, Campbell, Cheville, Citron, Constine, Cooper, Glare, Keefe, Koyyalagunta, Levy, Miaskowski, Otis-Green, Sloan, Bruera Tags: Pain Control, ASCO Guidelines, Quality of Life, Pain Control ASCO SPECIAL ARTICLE Source Type: research

Effects of Organizational Characteristics on Outcomes and Resource Use in Patients With Cancer Admitted to Intensive Care Units [Health Services and Outcomes]
Conclusion Organizational aspects, namely the implementation of protocols and presence of clinical pharmacists in the ICU, and close collaboration between oncologists and ICU teams are targets to improve mortality and resource use in critically ill patients with cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Soares, Bozza, Azevedo, Silva, Correa, Colombari, Torelly, Varaschin, Viana, Knibel, Damasceno, Espinoza, Ferez, Silveira, Lobo, Moraes, Lima, de Carvalho, do Brasil, Kahn, Angus, Salluh Tags: Prognostic Studies, Quality of Care, Outcomes Research, Supportive Care Health Services and Outcomes Source Type: research

Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival [Breast Cancer]
Conclusion The effect of age on survival of women with early breast cancer seems to vary by breast cancer subtype. Young age seems to be particularly prognostic in women with luminal breast cancers. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Partridge, Hughes, Warner, Ottesen, Wong, Edge, Theriault, Blayney, Niland, Winer, Weeks, Tamimi Tags: Epidemiology, Hormonal Therapy Breast Cancer Source Type: research

Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial [Gastrointestinal Cancer]
Conclusion mFOLFOX6-based preoperative chemoradiotherapy results in a higher pCR rate than fluorouracil-based treatment. Perioperative mFOLFOX6 alone had inferior results and a lower pCR rate than chemoradiotherapy but led to a similar downstaging rate as fluorouracil-radiotherapy, with less toxicity and fewer postoperative complications. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Deng, Chi, Lan, Wang, Chen, Cui, Chen, Cao, Wei, Peng, Huang, Cai, Zhao, Huang, Xu, Zhou, Wei, Zhang, Zheng, Huang, Zhou, Cai, Kang, Huang, Peng, Ren, Wang Tags: Clinical Trials, Surgery, Radiation, Chemotherapy, Combined Modality Gastrointestinal Cancer Source Type: research

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study [Hematologic Malignancy]
Conclusion This phase II study demonstrates that BeGEV is an effective salvage regimen able to induce CR in a high proportion of patients with relapsed or refractory HL before ASCT. These data provide a strong rationale for further development of the BeGEV regimen. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Santoro, Mazza, Pulsoni, Re, Bonfichi, Zilioli, Salvi, Merli, Anastasia, Luminari, Annechini, Gotti, Peli, Liberati, Di Renzo, Castagna, Giordano, Carlo-Stella Tags: Leukemia Hematologic Malignancy Source Type: research

Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes [Hematologic Malignancy]
Purpose WHO classification of myeloid malignancies is based mainly on the percentage of bone marrow (BM) blasts. This is considered from total nucleated cells (TNCs), unless there is erythroid-hyperplasia (erythroblasts ≥ 50%), calculated from nonerythroid cells (NECs). In these instances, when BM blasts are ≥ 20%, the disorder is classified as erythroleukemia, and when BM blasts are
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Arenillas, Calvo, Luno, Senent, Alonso, Ramos, Ardanaz, Pedro, Tormo, Marco, Montoro, Diez-Campelo, Brunet, Arrizabalaga, Xicoy, Andreu, Bonanad, Jerez, Nomdedeu, Ferrer, Sanz, Florensa Tags: Epidemiology, Diagnosis & Staging Hematologic Malignancy Source Type: research

Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States [AIDS-Related Cancer]
Purpose The biology of HIV-associated cancers may differ depending on immunologic and virologic context during development. Therefore, an understanding of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) relative to antiretroviral therapy (ART), virologic suppression, and CD4 count is important. Patients and Methods KS and NHL diagnoses during 1996 to 2011 were identified among patients with HIV infection in eight clinical cohorts in the United States. Among patients in routine HIV clinical care, the proportion of cases in categories of ART use, HIV RNA, and CD4 count at diagnosis were described across c...
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Yanik, Achenbach, Gopal, Coghill, Cole, Eron, Moore, Mathews, Drozd, Hamdan, Ballestas, Engels Tags: Incidence trends, Population and observational studies (SEER, WHI observational, etc.), Epidemiology, Diagnosis & Staging, Epidemiology, Diagnosis & Staging, Rhabdo & Other Soft Tissue Sarcomas: AIDS-Related Cancer Source Type: research

Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study [Urologic Oncology]
Purpose The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) has become unclear since the introduction of targeted therapies (TT). We sought to evaluate contemporary utilization rates of CN and to examine the survival benefit of CN compared with non-CN patients treated with TT. Methods We used the National Cancer Data Base to identify patients with clinical mRCC treated with TT between 2006 and 2013. The intervention of interest was CN. Multivariable logistic regression predicting receipt of CN was performed. Overall survival (OS) was examined using Cox regression models and incremental sur...
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Hanna, Sun, Meyer, Nguyen, Pal, Chang, de Velasco, Trinh, Choueiri Tags: Surgery, Chemotherapy, Combined Modality Urologic Oncology Source Type: research

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [Thoracic Oncology]
Conclusion P+G improved PFS compared with gefitinib alone in East Asian patients with advanced NS NSCLC and activating EGFR mutations. This combination may offer EGFR mutation–positive patients new treatment options and improved clinical outcomes compared with the current standard of care. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Cheng, Murakami, Yang, He, Nakagawa, Kang, Kim, Wang, Enatsu, Puri, Orlando, Yang Tags: Chemotherapy Thoracic Oncology Source Type: research